TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2019 DA - 2019// TI - Cancer statistics 2019 JO - CA Cancer J Clin VL - 69 ID - Siegel2019 ER - TY - JOUR AU - Ciardiello, F. AU - Tortora, G. PY - 2008 DA - 2008// TI - EGFR antagonists in cancer treatment JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMra0707704 DO - 10.1056/NEJMra0707704 ID - Ciardiello2008 ER - TY - JOUR AU - Troiani, T. AU - Napolitano, S. AU - Della Corte, C. M. AU - Martini, G. AU - Martinelli, E. AU - Morgillo, F. PY - 2016 DA - 2016// TI - Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence JO - ESMO Open VL - 1 UR - https://doi.org/10.1136/esmoopen-2016-000088 DO - 10.1136/esmoopen-2016-000088 ID - Troiani2016 ER - TY - JOUR AU - Sforza, V. AU - Martinelli, E. AU - Ciardiello, F. AU - Gambardella, V. AU - Napolitano, S. AU - Martini, G. PY - 2016 DA - 2016// TI - Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer JO - World J Gastroenterol VL - 22 UR - https://doi.org/10.3748/wjg.v22.i28.6345 DO - 10.3748/wjg.v22.i28.6345 ID - Sforza2016 ER - TY - JOUR AU - Russo, M. AU - Siravegna, G. AU - Blaszkowsky, L. S. AU - Corti, G. AU - Crisafulli, G. AU - Ahronian, L. G. PY - 2016 DA - 2016// TI - Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal Cancer JO - Cancer Discovery VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-15-1283 DO - 10.1158/2159-8290.CD-15-1283 ID - Russo2016 ER - TY - JOUR AU - Parseghian, C. M. AU - Loree, J. M. AU - Morris, V. K. AU - Liu, X. AU - Clifton, K. K. AU - Napolitano, S. PY - 2019 DA - 2019// TI - Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge JO - Ann Oncol VL - 1 UR - https://doi.org/10.1093/annonc/mdy509 DO - 10.1093/annonc/mdy509 ID - Parseghian2019 ER - TY - JOUR AU - Włodarczyk, M. AU - Włodarczyk, J. AU - Siwiński, P. AU - Sobolewska-Włodarczyk, A. AU - Fichna, J. PY - 2018 DA - 2018// TI - Genetic molecular subtypes in optimizing personalized therapy for metastatic colorectal Cancer JO - Curr Drug Targets VL - 19 UR - https://doi.org/10.2174/1389450119666180803122744 DO - 10.2174/1389450119666180803122744 ID - Włodarczyk2018 ER - TY - JOUR AU - Wang, W. AU - Kandimalla, R. AU - Huang, H. AU - Zhu, L. AU - Li, Y. AU - Gao, F. PY - 2019 DA - 2019// TI - Molecular subtyping of colorectal cancer: recent progress, new challenges and emerging opportunities JO - Semin Cancer Biol VL - 55 UR - https://doi.org/10.1016/j.semcancer.2018.05.002 DO - 10.1016/j.semcancer.2018.05.002 ID - Wang2019 ER - TY - JOUR AU - Dienstmann, R. AU - Salazar, R. AU - Tabernero, J. PY - 2018 DA - 2018// TI - Molecular subtypes and the evolution of treatment decisions in metastatic colorectal Cancer JO - Am Soc Clin Oncol Educ Book VL - 38 UR - https://doi.org/10.1200/EDBK_200929 DO - 10.1200/EDBK_200929 ID - Dienstmann2018 ER - TY - JOUR AU - Troiani, T. AU - Napolitano, S. AU - Vitagliano, D. AU - Morgillo, F. AU - Capasso, A. AU - Sforza, V. PY - 2014 DA - 2014// TI - Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2181 DO - 10.1158/1078-0432.CCR-13-2181 ID - Troiani2014 ER - TY - JOUR AU - Troiani, T. AU - Napolitano, S. AU - Martini, G. AU - Martinelli, E. AU - Cardone, C. AU - Normanno, N. PY - 2015 DA - 2015// TI - Maintenance treatment with Cetuximab and BAY86-9766 increases antitumor efficacy of Irinotecan plus Cetuximab in human colorectal Cancer Xenograft models JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0211 DO - 10.1158/1078-0432.CCR-15-0211 ID - Troiani2015 ER - TY - JOUR AU - Martinelli, E. AU - Morgillo, F. AU - Troiani, T. AU - Ciardiello, F. PY - 2017 DA - 2017// TI - Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK JO - Cancer Treat Rev VL - 53 UR - https://doi.org/10.1016/j.ctrv.2016.12.001 DO - 10.1016/j.ctrv.2016.12.001 ID - Martinelli2017 ER - TY - JOUR AU - Infante, J. R. AU - Fecher, L. A. AU - Falchook, G. S. AU - Nallapareddy, S. AU - Gordon, M. S. AU - Becerra, C. PY - 2012 DA - 2012// TI - Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70270-X DO - 10.1016/S1470-2045(12)70270-X ID - Infante2012 ER - TY - JOUR AU - Angelova, M. AU - Charoentong, P. AU - Hackl, H. AU - Fischer, M. L. AU - Snajder, R. AU - Krogsdam, A. M. PY - 2015 DA - 2015// TI - Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy JO - Genome Biol VL - 16 UR - https://doi.org/10.1186/s13059-015-0620-6 DO - 10.1186/s13059-015-0620-6 ID - Angelova2015 ER - TY - JOUR AU - Guinney, J. AU - Dienstmann, R. AU - Wang, X. AU - Reynies, A. AU - Schlicker, A. AU - Soneson, C. PY - 2015 DA - 2015// TI - The consensus molecular subtypes of colorectal cancer JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3967 DO - 10.1038/nm.3967 ID - Guinney2015 ER - TY - JOUR AU - Becht, E. AU - Reyniès, A. AU - Giraldo, N. A. AU - Pilati, C. AU - Buttard, B. AU - Lacroix, L. PY - 2016 DA - 2016// TI - Immune and stromal classification of colorectal Cancer is associated with molecular subtypes and relevant for precision immunotherapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2879 DO - 10.1158/1078-0432.CCR-15-2879 ID - Becht2016 ER - TY - JOUR AU - Dienstmann, R. AU - Vermeulen, L. AU - Guinney, J. AU - Kopetz, S. AU - Tejpar, S. AU - Tabernero, J. PY - 2017 DA - 2017// TI - Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer JO - Nat Rev Cancer VL - 17 UR - https://doi.org/10.1038/nrc.2017.24 DO - 10.1038/nrc.2017.24 ID - Dienstmann2017 ER - TY - JOUR AU - Troiani, T. AU - Martinelli, E. AU - Napolitano, S. PY - 2013 DA - 2013// TI - Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancercells JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0423 DO - 10.1158/1078-0432.CCR-13-0423 ID - Troiani2013 ER - TY - JOUR AU - Napolitano, S. AU - Martini, G. AU - Martinelli, E. AU - Belli, V. AU - Parascandolo, A. AU - Laukkanen, M. O. PY - 2017 DA - 2017// TI - Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation JO - Oncotarget. VL - 8 ID - Napolitano2017 ER - TY - JOUR AU - Napolitano, S. AU - Martini, G. AU - Martinelli, E. AU - Della Corte, C. M. AU - Morgillo, F. AU - Belli, V. PY - 2017 DA - 2017// TI - Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells JO - Oncotarget. VL - 8 ID - Napolitano2017 ER - TY - JOUR AU - Wolfle, S. J. AU - Strebovsky, J. AU - Bartz, H. AU - Sahr, A. AU - Arnold, C. AU - Kaiser, C. PY - 2011 DA - 2011// TI - PD- L1 expression on tolerogenic APCs is controlled by STAT-3 JO - Eur J Immunol VL - 41 UR - https://doi.org/10.1002/eji.201040979 DO - 10.1002/eji.201040979 ID - Wolfle2011 ER - TY - JOUR AU - Chen, J. AU - Jiang, C. C. AU - Jin, L. AU - Zhang, X. D. PY - 2015 DA - 2015// TI - Regulation of PD-L1: a novel role of pro-survival signalling in cancer JO - Annals of Oncology VL - 27 UR - https://doi.org/10.1093/annonc/mdv615 DO - 10.1093/annonc/mdv615 ID - Chen2015 ER - TY - JOUR AU - Lee, H. J. AU - Zhuang, G. AU - Cao, Y. AU - Du, P. AU - Kim, H. J. AU - Settleman, J. PY - 2014 DA - 2014// TI - Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells JO - Cancer Cell VL - 26 UR - https://doi.org/10.1016/j.ccr.2014.05.019 DO - 10.1016/j.ccr.2014.05.019 ID - Lee2014 ER - TY - JOUR AU - Ghebeh, H. AU - Lehe, C. AU - Barhoush, E. AU - Al-Romaih, K. AU - Tulbah, A. AU - Al-Alwan, M. PY - 2010 DA - 2010// TI - Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule JO - Breast Cancer Res VL - 12 UR - https://doi.org/10.1186/bcr2605 DO - 10.1186/bcr2605 ID - Ghebeh2010 ER - TY - JOUR AU - Satelli, A. AU - Batth, I. S. AU - Brownlee, Z. AU - Rojas, C. AU - Meng, Q. H. AU - Kopetz, S. PY - 2016 DA - 2016// TI - Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep28910 DO - 10.1038/srep28910 ID - Satelli2016 ER - TY - JOUR AU - Ganesh, K. AU - Stadler, Z. K. AU - Cercek, A. AU - Mendelsohn, R. B. AU - Shia, J. AU - Segal, N. H. PY - 2019 DA - 2019// TI - Immunotherapy in colorectal cancer: rationale, challenges and potential JO - Nat Rev Gastroenterol Hepatol VL - 16 UR - https://doi.org/10.1038/s41575-019-0126-x DO - 10.1038/s41575-019-0126-x ID - Ganesh2019 ER - TY - STD TI - Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330–07. ID - ref27 ER - TY - JOUR AU - Roepman, P. AU - Schlicker, A. AU - Tabernero, J. AU - Majewski, I. AU - Tian, S. AU - Moreno, V. PY - 2014 DA - 2014// TI - Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition JO - Int J Cancer VL - 134 UR - https://doi.org/10.1002/ijc.28387 DO - 10.1002/ijc.28387 ID - Roepman2014 ER - TY - JOUR AU - Budinska, E. AU - Popovici, V. AU - Tejpar, S. AU - D'Ario, G. AU - Lapique, N. AU - Sikora, K. O. PY - 2013 DA - 2013// TI - Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer JO - J Pathol VL - 231 UR - https://doi.org/10.1002/path.4212 DO - 10.1002/path.4212 ID - Budinska2013 ER - TY - JOUR AU - Schlicker, A. AU - Beran, G. AU - Chresta, C. M. AU - McWalter, G. AU - Pritchard, A. AU - Weston, S. PY - 2012 DA - 2012// TI - Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines JO - BMC Med Genet VL - 5 ID - Schlicker2012 ER - TY - JOUR AU - Sadanandam, A. AU - Lyssiotis, C. A. AU - Homicsko, K. AU - Collisson, E. A. AU - Gibb, W. J. AU - Wullschleger, S. PY - 2013 DA - 2013// TI - A colorectal cancer classification system that associates cellular phenotype and responses to therapy JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3175 DO - 10.1038/nm.3175 ID - Sadanandam2013 ER - TY - JOUR AU - Sousa, E. M. F. AU - Wang, X. AU - Jansen, M. AU - Fessler, E. AU - Trinh, A. AU - Rooij, L. P. PY - 2013 DA - 2013// TI - Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3174 DO - 10.1038/nm.3174 ID - Sousa2013 ER - TY - JOUR AU - Marisa, L. AU - Reynies, A. AU - Duval, A. AU - Selves, J. AU - Gaub, M. P. AU - Vescovo, L. PY - 2013 DA - 2013// TI - Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value JO - PLoS Med VL - 10 UR - https://doi.org/10.1371/journal.pmed.1001453 DO - 10.1371/journal.pmed.1001453 ID - Marisa2013 ER - TY - JOUR AU - Perez-Villamil, B. AU - Romera-Lopez, A. AU - Hernandez-Prieto, S. AU - Lopez-Campos, G. AU - Calles, A. AU - Lopez-Asenjo, J. A. PY - 2012 DA - 2012// TI - Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior JO - BMC Cancer VL - 12 UR - https://doi.org/10.1186/1471-2407-12-260 DO - 10.1186/1471-2407-12-260 ID - Perez-Villamil2012 ER - TY - JOUR AU - Paucek, R. D. AU - Baltimore, D. AU - Li, G. PY - 2019 DA - 2019// TI - The cellular immunotherapy revolution: arming the immune system for precision therapy JO - Trends Immunol VL - 40 UR - https://doi.org/10.1016/j.it.2019.02.002 DO - 10.1016/j.it.2019.02.002 ID - Paucek2019 ER - TY - JOUR AU - Overman, M. J. AU - McDermott, R. AU - Leach, J. L. AU - Lonardi, S. AU - Lenz, H. J. AU - Morse, M. A. PY - 2017 DA - 2017// TI - Nivolumab in patients with metastatic DNA mismatch repair deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30422-9 DO - 10.1016/S1470-2045(17)30422-9 ID - Overman2017 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Grasso, C. S. AU - Giannakis, M. AU - Wells, D. K. AU - Hamada, T. AU - Mu, X. J. AU - Quist, M. PY - 2018 DA - 2018// TI - Genetic mechanisms of immune evasion in colorectal Cancer JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-1327 DO - 10.1158/2159-8290.CD-17-1327 ID - Grasso2018 ER - TY - JOUR AU - Lal, N. AU - White, B. S. AU - Goussous, G. AU - Pickles, O. AU - Mason, M. J. AU - Beggs, A. D. PY - 2018 DA - 2018// TI - KRAS mutation and consensus molecular subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-1090 DO - 10.1158/1078-0432.CCR-17-1090 ID - Lal2018 ER - TY - JOUR AU - Ebert, P. J. R. AU - Cheung, J. AU - Yang, Y. AU - McNamara, E. AU - Hong, R. AU - Moskalenko, M. PY - 2016 DA - 2016// TI - MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade JO - Immunity. VL - 44 UR - https://doi.org/10.1016/j.immuni.2016.01.024 DO - 10.1016/j.immuni.2016.01.024 ID - Ebert2016 ER - TY - JOUR AU - Hellmann, M. D. AU - Kim, T. W. AU - Lee, C. B. AU - Goh, B. C. AU - Miller, W. H. AU - Oh, D. Y. PY - 2019 DA - 2019// TI - Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz113 DO - 10.1093/annonc/mdz113 ID - Hellmann2019 ER - TY - STD TI - Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019; 20:849:61. ID - ref42 ER - TY - JOUR AU - MacDonald, F. AU - Zaiss, D. M. W. PY - 2017 DA - 2017// TI - The immune System’s contribution to the clinical efficacy of EGFR antagonist treatment JO - Front Pharmacol VL - 8 UR - https://doi.org/10.3389/fphar.2017.00575 DO - 10.3389/fphar.2017.00575 ID - MacDonald2017 ER - TY - STD TI - Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355-63. ID - ref44 ER - TY - JOUR AU - Azuma, K. AU - Ota, K. AU - Kawahara, A. AU - Hattori, S. AU - Iwama, E. AU - Harada, T. AU - Matsumoto, K. AU - Takayama, K. AU - Takamori, S. AU - Kage, M. AU - Hoshino, T. AU - Nakanishi, Y. AU - Okamoto, I. PY - 2014 DA - 2014// TI - Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer JO - Annals of Oncology VL - 25 UR - https://doi.org/10.1093/annonc/mdu242 DO - 10.1093/annonc/mdu242 ID - Azuma2014 ER - TY - STD TI - Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR Activation Mediates the ImmuneEscape in EGFR Driven NSCLC: Implication for Optional ImmuneTargeted Therapy for NSCLC Patients with EGFR Mutation.J Thorac Oncol. 2015;10:910-23. ID - ref46 ER -